PROMUS Element Plus US Post-Approval Study

Completed · Phase 4

Conditions studied: Coronary Artery Disease

In brief

This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice. Patients will have symptomatic heart disease or documented silent ischemia. This is a prospective, open-label consecutively-enrolling study. Clinical follow-up is through 5 years. Approximately 2,689 patients are to be enrolled in up to 65 centers in the United States.

Key facts

Study ID
NCT01589978
Run by
Boston Scientific Corporation
People needed
2681
Starts
2012-05-01
Expected to finish
2018-06-01
Last updated by the study team
2018-07-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.